Geode Capital Management’s Elevation Oncology ELEV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-538,656
| Closed | -$198K | – | 4500 |
|
|
2025
Q2 | $198K | Sell |
538,656
-647,663
| -55% | -$216K | ﹤0.01% | 3876 |
|
|
2025
Q1 | $307K | Buy |
1,186,319
+28,747
| +2% | +$16.4K | ﹤0.01% | 3712 |
|
|
2024
Q4 | $651K | Buy |
1,157,572
+47,487
| +4% | +$28K | ﹤0.01% | 3522 |
|
|
2024
Q3 | $666K | Buy |
1,110,085
+78,509
| +8% | +$116K | ﹤0.01% | 3497 |
|
|
2024
Q2 | $2.79M | Buy |
1,031,576
+683,143
| +196% | +$2.57M | ﹤0.01% | 3014 |
|
|
2024
Q1 | $1.79M | Buy |
348,433
+118,297
| +51% | +$383K | ﹤0.01% | 3152 |
|
|
2023
Q4 | $124K | Hold |
230,136
| – | – | ﹤0.01% | 4114 |
|
|
2023
Q3 | $153K | Buy |
230,136
+93,971
| +69% | +$95K | ﹤0.01% | 4088 |
|
|
2023
Q2 | $207K | Buy |
136,165
+5,785
| +4% | +$15.3K | ﹤0.01% | 4026 |
|
|
2023
Q1 | $248K | Buy |
130,380
+40,037
| +44% | +$51.7K | ﹤0.01% | 3941 |
|
|
2022
Q4 | $85K | Sell |
90,343
-284
| -0.3% | -$288 | ﹤0.01% | 4449 |
|
|
2022
Q3 | $102K | Buy |
90,627
+64,361
| +245% | +$81K | ﹤0.01% | 4566 |
|
|
2022
Q2 | $36K | Hold |
26,266
| – | – | ﹤0.01% | 4847 |
|
|
2022
Q1 | $66K | Buy |
26,266
+5,245
| +25% | +$21K | ﹤0.01% | 4757 |
|
|
2021
Q4 | $126K | Buy |
21,021
+8,865
| +73% | +$61.2K | ﹤0.01% | 4648 |
|
|
2021
Q3 | $94K | Buy |
+12,156
| New | +$131K | ﹤0.01% | 4691 |
|
Other funds holding ELEV
Geode Capital Management's ELEV Position: Q3 2025 in Review
Geode Capital Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 538,656 shares — an estimated $198K sold.
Geode Capital Management first reported a position in ELEV in Q3 2021 and held it in 16 quarters. The position peaked at $2.79M in Q2 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.
- Geode Capital Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
- Geode Capital Management sold 538,656 Elevation Oncology shares in Q3 2025, an estimated $198K.
- Geode Capital Management first reported a position in Elevation Oncology in Q3 2021 and held it in 16 quarters.
- Geode Capital Management's Elevation Oncology position peaked at $2.79M in Q2 2024.
- 1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.
Based on Geode Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.